.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03C_Estrogens.G03CA01_Ethinylestradiol.Ethinylestradiol .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03C_Estrogens.G03CA01_Ethinylestradiol.Ethinylestradiol| name: | Ethinylestradiol |
| ATC code: | G03CA01 | route: | oral |
| n-compartments | 2 |
Ethinylestradiol is a synthetic derivative of the natural estrogen estradiol. It is primarily used as an oral contraceptive, either alone or in combination with progestins, for the prevention of pregnancy. It is approved for clinical use and is a common component of combined oral contraceptive pills.
Pharmacokinetic parameters reported for healthy adult females after a single oral dose.
Mohamed, MF, et al., & Othman, AA (2019). The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. Journal of clinical pharmacology 59(4) 510–516. DOI:10.1002/jcph.1350 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30500075
Kiriwat, O, & Fotherby, K (1983). Pharmacokinetics of oral contraceptive steroids after morning or evening administration. Contraception 27(2) 153–160. DOI:10.1016/0010-7824(83)90086-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/6851554
Ezuruike, U, et al., & Rowland Yeo, K (2018). Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. Clinical pharmacology and therapeutics 104(6) 1229–1239. DOI:10.1002/cpt.1085 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29637542